Schijvens, Anne M. http://orcid.org/0000-0003-2418-8928
Teeninga, Nynke
Dorresteijn, Eiske M. http://orcid.org/0000-0002-1290-4395
Teerenstra, Steven http://orcid.org/0000-0003-4103-7451
Webb, Nicholas J. http://orcid.org/0000-0001-8572-5446
Schreuder, Michiel F. http://orcid.org/0000-0001-9725-4856
Funding for this research was provided by:
Nierstichting (15OKG16)
Article History
Received: 14 January 2021
Revised: 9 March 2021
Accepted: 16 March 2021
First Online: 28 March 2021
Declarations
:
: PREDNOS trial ISRCTN16645249, EudraCT 2010-022489-29, approved by the North West 7 Research Ethics Committee, Manchester, UK (10/H1008/122). The trial was carried out under a clinical trial authorization in accordance with the Medicines for Human Use (Clinical Trials) Regulations (21761/0255/001-0001) and conducted in accordance with the Declaration of Helsinki.Trial Teeninga et al.: NTR255, approved by the medical ethics committee of the Erasmus University Medical Center in Rotterdam, the Netherlands.
: All participants of the included trials signed informed consent to participate in the respective trials. NA for the IPD meta-analysis.
: NA
: Prof. Webb is currently a full-time employee at Novartis Pharma AG. Dr. Schijvens and prof. Schreuder report a grant from the Dutch Kidney Foundation (awarded to prof. Schreuder) during the conduct of the study.